NRSN
Neurosense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.42
+10.94%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.33
From 52W high−94.27%
Volume23208.00
Market cap$2.69M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.33
From 52W high
−94.27%
Volume
23208.00
Market cap
$2.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
18.3
MomentumView details →
1D Return
+10.94%
YTD Return
−91.42%
SummaryUpdated Dec 1, 2025
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Herzliya, Israel. The company went public in December 2021 and focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense is currently advancing its lead drug candidate through clinical trials while building a pipeline of potential treatments for some of the most challenging neurological conditions affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
Health Canada confirmed a March 2027 filing timeline for NeuroSense Therapeutics' PrimeC Canadian ALS submission, which will include new neurofilament light chain analysis.2d agoNeuroSense Therapeutics Ltd. announced that it will present clinical and biomarker evidence from its NeuroSense Therapeutics Ltd. program at NEALS 2026 to inform PrimeC's Phase 3 development strategy.6d agoNeuroSense Therapeutics filed a U.S. patent application seeking protection for PrimeC use in traumatic brain injury, including concussion, blast-related brain injury and chronic traumatic encephalopathy.16d ago